Lilian Basso

Lilian Basso

Auto-generated profile, based on publicly available information

Lilian Basso

University of Toulouse, Inserm, CNRS, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
NSNadine Serhan
Nadine Serhan
LBLilian Basso
Lilian Basso
RSRiccardo Sibilano
Riccardo Sibilano
CPCamille Petitfils
Camille Petitfils
JMJames Meixiong
James Meixiong
NGNicolas Gaudenzio
Nicolas Gaudenzio

18 July 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MTMarie Tauber
Marie Tauber
LBLilian Basso
Lilian Basso
JMJeremy Martin
Jeremy Martin
LBLuciana Bostan
Luciana Bostan
MPMarlene Magalhaes Pinto
Marlene Magalhaes Pinto
NGNicolas Gaudenzio
Nicolas Gaudenzio
Mast cells (MCs) are tissue-resident immune cells that exhibit homeostatic and neuron-associated functions. Here, we combined whole-tissue imaging and single-cell RNA sequencing datasets to generate a pan-organ analysis of MCs in mice and humans at steady state. In mice, we identify two mutually exclusive MC populations, MrgprB2+ connective tissue–type MCs and MrgprB2neg mucosal-type MCs, with specific transcriptomic core signatures. While MrgprB2+ MCs develop in utero independently of the bone marrow, MrgprB2neg MCs develop after birth and are renewed by bone marrow progenitors. In humans, we unbiasedly identify six MC clusters/states (MC1–6) distributed across 12 organs with different transcriptomic core signatures. MC1 are preferentially enriched in the skin and lungs, MC2, MC3, and MC4 in the skin and bladder, MC5 in the lymph node and vasculature, and MC6 in the trachea and lungs. This comprehensive analysis offers valuable insights into the natural diversity of MC subtypes in both mice and humans.

2 April 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
LBLilian Basso
Lilian Basso
RAReem Aboushousha
Reem Aboushousha
CFChurmy Yong Fan
Churmy Yong Fan
MIMircea Iftinca
Mircea Iftinca
HMHelvira Melo
Helvira Melo
CAChristophe Altier
Christophe Altier
Inflammation-induced TRPV1 activity promotes pain relief by relocalizing β-arrestin2.

15 June 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MDManon Defaye
Manon Defaye
MIMircea C. Iftinca
Mircea C. Iftinca
VGVinicius M. Gadotti
Vinicius M. Gadotti
LBLilian Basso
Lilian Basso
NANasser S. Abdullah
Nasser S. Abdullah
CAChristophe Altier
Christophe Altier
The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase known for its oncogenic potential that is involved in the development of the peripheral and central nervous system. ALK receptor ligands ALKAL1 and ALKAL2 were recently found to promote neuronal differentiation and survival. Here, we show that inflammation or injury enhanced ALKAL2 expression in a subset of TRPV1+ sensory neurons. Notably, ALKAL2 was particularly enriched in both mouse and human peptidergic nociceptors, yet weakly expressed in nonpeptidergic, large-diameter myelinated neurons or in the brain. Using a coculture expression system, we found that nociceptors exposed to ALKAL2 exhibited heightened excitability and neurite outgrowth. Intraplantar CFA or intrathecal infusion of recombinant ALKAL2 led to ALK phosphorylation in the lumbar dorsal horn of the spinal cord. Finally, depletion of ALKAL2 in dorsal root ganglia or blocking ALK with clinically available compounds crizotinib or lorlatinib reversed thermal hyperalgesia and mechanical allodynia induced by inflammation or nerve injury, respectively. Overall, our work uncovers the ALKAL2/ALK signaling axis as a central regulator of nociceptor-induced sensitization. We propose that clinically approved ALK inhibitors used for non–small cell lung cancer and neuroblastomas could be repurposed to treat persistent pain conditions.

1 April 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
NSNadine Serhan
Nadine Serhan
NCNicolas Cenac
Nicolas Cenac
LBLilian Basso
Lilian Basso
NGNicolas Gaudenzio
Nicolas Gaudenzio

19 March 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MDManon Defaye
Manon Defaye
ABAmyaouch Bradaia
Amyaouch Bradaia
NANasser S. Abdullah
Nasser S. Abdullah
FAFrancina Agosti
Francina Agosti
MIMircea Iftinca
Mircea Iftinca
CAChristophe Altier
Christophe Altier
Inflammation and pain are intertwined responses to injury, infection, or chronic diseases. While acute inflammation is essential in determining pain resolution and opioid analgesia, maladaptive processes occurring during resolution can lead to the transition to chronic pain. Here we found that inflammation activates the cytosolic DNA–sensing protein stimulator of IFN genes (STING) in dorsal root ganglion nociceptors. Neuronal activation of STING promotes signaling through TANK-binding kinase 1 (TBK1) and triggers an IFN-β response that mediates pain resolution. Notably, we found that mice expressing a nociceptor-specific gain-of-function mutation in STING exhibited an IFN gene signature that reduced nociceptor excitability and inflammatory hyperalgesia through a KChIP1-Kv4.3 regulation. Our findings reveal a role of IFN-regulated genes and KChIP1 downstream of STING in the resolution of inflammatory pain.